H1 2024 net Sales reached SEK204m, a 319% increase year-on-year, following the reverse acquisition of Infrateq and the acquisition of Xpeedio Support Solutions AB. Due to extraordinary costs associated with the acquisitions, some one-off items impacted profitability in H1 2024. We are adjusting our Base Case from SEK3.4 to SEK3.3. The new valuation range is SEK2.1 - 5.50 (previously SEK2.6 - 5.7).

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking.www.redeye.se/